We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
Read MoreHide Full Article
HMS Holdings Corp. reported adjusted earnings of 30 cents per share in third-quarter 2019, which surpassed the Zacks Consensus Estimate of 27 cents by 11.1%. However, the bottom line declined 3.2% from the year-ago quarter.
Revenues of $146.8 million missed the Zacks Consensus Estimate by 11.3%. Moreover, the top line declined 4.8% on a year-over-year basis.
Q3 Segmental Analysis by Product
Analytical Services
Revenues at this segment were $52.2 million in the third quarter, up 7.6% year over year.
Within Analytical Services, PI revenues (excluding Medicare RAC) amounted to $37 million, up 11.4% year over year.
PHM revenues totaled $15.2 million in the quarter under review, down 0.7% on a year-over-year basis.
COB
Revenues at the COB segment amounted to $94.6 million in the third quarter, down 10.5% year over year.
HMS Holdings Corp Price, Consensus and EPS Surprise
Total cost of services in the reported quarter was $101.5 million, down 0.3% year over year.
Gross profit came in at $45.3 million, which declined 13.6% from the prior-year quarter figure. Gross margin was 30.9% of net revenues, down 300 bps year over year.
Selling, general and administrative expenses totaled $28.2 million, up 0.2% year over year. Operating income in the third quarter was $17.1 million, down 29.6% from the year-ago quarter. Operating margin was 11.6%, down 410 bps from the prior-year quarter.
Financial Update
Cash and cash equivalents amounted to $280.6 million, up 4.4% sequentially.
Net cash provided by operating activities for the nine months ended Sep 30, 2019, came in at $112.9 million, compared with $55.5 million reported in the year-ago quarter.
Guidance Revised
For 2019, the company now anticipates revenues between $630 million and $640 million (down from the previously guided range of $650-$660 million). This indicates an improvement of 5.4-7% from the prior-year quarter. The mid-point of $635 million is higher than the Zacks Consensus Estimate of $634.1 million.
Net income is expected in the band of $89-$94 million (up from the prior band of $85-$90 million), suggesting growth of 61.8-70.9% from the year-ago reported figure.
Adjusted EBITDA is expected in the range of $182-$187 million (down from the previously guided range of $185-$190 million), suggesting improvement of 12.3-15.4% from the year-ago comparable period.
Summing Up
HMS Holdings ended third-quarter 2019 on a mixed note, wherein the bottom line beat the Zacks Consensus Estimate, while the top line missed the same. The stock continues to benefit from Analytical Services unit. Strong 2019 outlook also instills investor optimism in the stock.
However, cut throat competition in the U.S. medical cost containment space remains a concern. Moreover, the company witnessed contraction in both gross and operating margins in the quarter under review.
Zacks Rank
Currently, HMS Holdings carries a Zacks Rank #4 (Sell).
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%.
ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
HMS Holdings Corp. reported adjusted earnings of 30 cents per share in third-quarter 2019, which surpassed the Zacks Consensus Estimate of 27 cents by 11.1%. However, the bottom line declined 3.2% from the year-ago quarter.
Revenues of $146.8 million missed the Zacks Consensus Estimate by 11.3%. Moreover, the top line declined 4.8% on a year-over-year basis.
Q3 Segmental Analysis by Product
Analytical Services
Revenues at this segment were $52.2 million in the third quarter, up 7.6% year over year.
Within Analytical Services, PI revenues (excluding Medicare RAC) amounted to $37 million, up 11.4% year over year.
PHM revenues totaled $15.2 million in the quarter under review, down 0.7% on a year-over-year basis.
COB
Revenues at the COB segment amounted to $94.6 million in the third quarter, down 10.5% year over year.
HMS Holdings Corp Price, Consensus and EPS Surprise
HMS Holdings Corp price-consensus-eps-surprise-chart | HMS Holdings Corp Quote
Margin Analysis
Total cost of services in the reported quarter was $101.5 million, down 0.3% year over year.
Gross profit came in at $45.3 million, which declined 13.6% from the prior-year quarter figure. Gross margin was 30.9% of net revenues, down 300 bps year over year.
Selling, general and administrative expenses totaled $28.2 million, up 0.2% year over year. Operating income in the third quarter was $17.1 million, down 29.6% from the year-ago quarter. Operating margin was 11.6%, down 410 bps from the prior-year quarter.
Financial Update
Cash and cash equivalents amounted to $280.6 million, up 4.4% sequentially.
Net cash provided by operating activities for the nine months ended Sep 30, 2019, came in at $112.9 million, compared with $55.5 million reported in the year-ago quarter.
Guidance Revised
For 2019, the company now anticipates revenues between $630 million and $640 million (down from the previously guided range of $650-$660 million). This indicates an improvement of 5.4-7% from the prior-year quarter. The mid-point of $635 million is higher than the Zacks Consensus Estimate of $634.1 million.
Net income is expected in the band of $89-$94 million (up from the prior band of $85-$90 million), suggesting growth of 61.8-70.9% from the year-ago reported figure.
Adjusted EBITDA is expected in the range of $182-$187 million (down from the previously guided range of $185-$190 million), suggesting improvement of 12.3-15.4% from the year-ago comparable period.
Summing Up
HMS Holdings ended third-quarter 2019 on a mixed note, wherein the bottom line beat the Zacks Consensus Estimate, while the top line missed the same. The stock continues to benefit from Analytical Services unit. Strong 2019 outlook also instills investor optimism in the stock.
However, cut throat competition in the U.S. medical cost containment space remains a concern. Moreover, the company witnessed contraction in both gross and operating margins in the quarter under review.
Zacks Rank
Currently, HMS Holdings carries a Zacks Rank #4 (Sell).
Earnings of Other MedTech Majors at a Glance
Some other top-ranked stocks that reported solid results this earning season are Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%.
ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>